Linked Life Data

3207991

Source:http://linkedlifedata.com/resource/pubmed/id/3207991

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3207991rdf:typepubmed:Citationlld:pubmed
pubmed-article:3207991lifeskim:mentionsumls-concept:C0999699lld:lifeskim
pubmed-article:3207991lifeskim:mentionsumls-concept:C0006280lld:lifeskim
pubmed-article:3207991lifeskim:mentionsumls-concept:C0028066lld:lifeskim
pubmed-article:3207991lifeskim:mentionsumls-concept:C0032824lld:lifeskim
pubmed-article:3207991lifeskim:mentionsumls-concept:C0056506lld:lifeskim
pubmed-article:3207991lifeskim:mentionsumls-concept:C1412820lld:lifeskim
pubmed-article:3207991lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:3207991lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:3207991pubmed:issue3lld:pubmed
pubmed-article:3207991pubmed:dateCreated1989-2-16lld:pubmed
pubmed-article:3207991pubmed:abstractText1. The potential of the potassium channel activator, cromakalim (BRL 34915), as a bronchodilator has been evaluated in guinea-pig models in comparison with nifedipine. Some effects of the compounds on guinea-pig tracheal spirals have been studied in an attempt to elucidate their different efficacies in vivo. 2. When given by the intraduodenal route to anaesthetized guinea-pigs, cromakalim (3 and 10 mg kg-1) inhibited 5-hydroxytryptamine (5-HT)-induced bronchospasm for at least 60 min. When given by the i.v. route, the dose of cromakalim producing 50% inhibition of the 5-HT response was 84 micrograms kg-1. Nifedipine failed to show any protective effect up to 100 micrograms kg-1, i.v. and was lethal at higher dose levels. 3. Cromakalim protected conscious guinea-pigs from asphyxic collapse in response to histamine aerosol. The maximal effect occurred 60 min following oral dosing, with 2.5 mg kg-1 providing complete protection for almost half of the animals. Nifedipine had only a weak protective effect even at a high dose level of 50 mg kg-1, p.o. 4. Cromakalim prolonged the time before convulsive cough in response to an antigen challenge in actively sensitized guinea-pigs. Its minimum protective dose was 1 mg kg-1, p.o. Nifedipine (50 mg kg-1, p.o.) was ineffective. 5. Cromakalim inhibited both spontaneous and prostaglandin E2-induced tone in guinea-pig isolated tracheal spirals with IC50 values, relative to the maximum inhibition achieved by isoprenaline (10(-3)M), of 1.1 x 10(-6)M and 8.9 x 10(-7)M, respectively. Its maximal effect was 89% of that produced by isoprenaline. Removal of the epithelium did not influence its activity. Studies using the two enantiomers showed that the activity of cromakalim resided almost entirely in the (-)-enantiomer. 6. Nifedipine (2 x 10-SM) achieved only 49% of the relaxant effect of 10 -3M isoprenaline in isolated tracheal spirals. Addition of cromakalim (10- 5 M) at the end of the nifedipine concentrationresponse experiment caused further relaxation to 94% of the effect of isoprenaline. 7. It is concluded that cromakalim has greater potential than nifedipine as a bronchodilator. It appears that opening of potassium channels, with consequent hyperpolarization and stabilization of the membrane potential, prevents calcium entering the cytosol through routes that are unaffected by calcium entry blockers.lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:languageenglld:pubmed
pubmed-article:3207991pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:citationSubsetIMlld:pubmed
pubmed-article:3207991pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3207991pubmed:statusMEDLINElld:pubmed
pubmed-article:3207991pubmed:monthNovlld:pubmed
pubmed-article:3207991pubmed:issn0007-1188lld:pubmed
pubmed-article:3207991pubmed:authorpubmed-author:TaylorJ FJFlld:pubmed
pubmed-article:3207991pubmed:authorpubmed-author:BuckleD RDRlld:pubmed
pubmed-article:3207991pubmed:authorpubmed-author:TaylorS GSGlld:pubmed
pubmed-article:3207991pubmed:authorpubmed-author:ArchJ RJRlld:pubmed
pubmed-article:3207991pubmed:authorpubmed-author:ClarkeG DGDlld:pubmed
pubmed-article:3207991pubmed:authorpubmed-author:BumsteadJJlld:pubmed
pubmed-article:3207991pubmed:issnTypePrintlld:pubmed
pubmed-article:3207991pubmed:volume95lld:pubmed
pubmed-article:3207991pubmed:ownerNLMlld:pubmed
pubmed-article:3207991pubmed:authorsCompleteYlld:pubmed
pubmed-article:3207991pubmed:pagination763-70lld:pubmed
pubmed-article:3207991pubmed:dateRevised2010-4-19lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:meshHeadingpubmed-meshheading:3207991-...lld:pubmed
pubmed-article:3207991pubmed:year1988lld:pubmed
pubmed-article:3207991pubmed:articleTitleEvaluation of the potassium channel activator cromakalim (BRL 34915) as a bronchodilator in the guinea-pig: comparison with nifedipine.lld:pubmed
pubmed-article:3207991pubmed:affiliationBeecham Pharmaceuticals Research Division, Biosciences Research Centre, Epsom, Surrey.lld:pubmed
pubmed-article:3207991pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3207991pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3207991pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3207991lld:pubmed